Cargando…
Submission for: Poster presentation at ANCIPS 2022: Allergic dermatitis with use of sublingual Buprenorphine: A rare case report
INTRODUCTION: Buprenorphine, a semi-synthetic opiate alkaloid derivative used for treatment of opioid dependence(1). Pruritis has been reported as a side effect with intramuscular and supra-dermal patch of buprenorphine and less common with oral/sublingual use of Buprenorphine. CASE REPORT: 19 years...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9129467/ http://dx.doi.org/10.4103/0019-5545.341979 |
_version_ | 1784712761803014144 |
---|---|
author | Gracy*, Dr BK Sharma**, Dr Mini Kataria, Dr Dinesh Kukreti, Dr Prerna |
author_facet | Gracy*, Dr BK Sharma**, Dr Mini Kataria, Dr Dinesh Kukreti, Dr Prerna |
author_sort | Gracy*, Dr BK |
collection | PubMed |
description | INTRODUCTION: Buprenorphine, a semi-synthetic opiate alkaloid derivative used for treatment of opioid dependence(1). Pruritis has been reported as a side effect with intramuscular and supra-dermal patch of buprenorphine and less common with oral/sublingual use of Buprenorphine. CASE REPORT: 19 years male presented to OPD of a tertiary care center with history of consuming smack in a chasing pattern for past 9 years, associated with tolerance, withdrawal, inability control the urge, craving and significant socio-occupational dysfunction due to opioid use. He had past history of conduct disorder. Patient was diagnosed with Mental and behavioral disorder due to opioid use, dependent pattern (ICD-10). For opioid substitution he was initiated with tablet buprenorphine sublingual (4 mg), after 1 day later he developed skin reaction- itching and erythema and then vesicular lesion. Consultation liaison with Dermatology department was done for evaluation of the allergic reaction and a drug re-challenge trial to assess for hypersensitivity was done with informed written consent of patient. There was increase in eosinophil counts from a differential count of 5% to 15% after re-administration of sublingual Buprenorphine suggestive of opioid related allergic dermatitis. The symptoms of intermittent itching was reported and managed with Tablet cetirizine 10 mg and local applicant Mometasone and Fusidic acid combination. However, on discontinuation of tablet buprenorphine new lesion didn't erupt whereas old lesion gradually healed. His Buprenorphine was discontinued and symptomatic management was done for withdrawal symptoms. DISCUSSION: The aetiology of opioid-induced itching is unknown but may be due to either a direct central effect or to histamine release. Reports of allergic contact dermatitis are common with Buprenorphine patch, though uncommon with sublingual Buprenorphine use. CONCLUSION: The present report describes allergic dermatitis is an uncommon drug reaction with sublingual Buprenorphine use and hence should be dealt vigilantly. |
format | Online Article Text |
id | pubmed-9129467 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-91294672022-05-25 Submission for: Poster presentation at ANCIPS 2022: Allergic dermatitis with use of sublingual Buprenorphine: A rare case report Gracy*, Dr BK Sharma**, Dr Mini Kataria, Dr Dinesh Kukreti, Dr Prerna Indian J Psychiatry Abstract- Poster INTRODUCTION: Buprenorphine, a semi-synthetic opiate alkaloid derivative used for treatment of opioid dependence(1). Pruritis has been reported as a side effect with intramuscular and supra-dermal patch of buprenorphine and less common with oral/sublingual use of Buprenorphine. CASE REPORT: 19 years male presented to OPD of a tertiary care center with history of consuming smack in a chasing pattern for past 9 years, associated with tolerance, withdrawal, inability control the urge, craving and significant socio-occupational dysfunction due to opioid use. He had past history of conduct disorder. Patient was diagnosed with Mental and behavioral disorder due to opioid use, dependent pattern (ICD-10). For opioid substitution he was initiated with tablet buprenorphine sublingual (4 mg), after 1 day later he developed skin reaction- itching and erythema and then vesicular lesion. Consultation liaison with Dermatology department was done for evaluation of the allergic reaction and a drug re-challenge trial to assess for hypersensitivity was done with informed written consent of patient. There was increase in eosinophil counts from a differential count of 5% to 15% after re-administration of sublingual Buprenorphine suggestive of opioid related allergic dermatitis. The symptoms of intermittent itching was reported and managed with Tablet cetirizine 10 mg and local applicant Mometasone and Fusidic acid combination. However, on discontinuation of tablet buprenorphine new lesion didn't erupt whereas old lesion gradually healed. His Buprenorphine was discontinued and symptomatic management was done for withdrawal symptoms. DISCUSSION: The aetiology of opioid-induced itching is unknown but may be due to either a direct central effect or to histamine release. Reports of allergic contact dermatitis are common with Buprenorphine patch, though uncommon with sublingual Buprenorphine use. CONCLUSION: The present report describes allergic dermatitis is an uncommon drug reaction with sublingual Buprenorphine use and hence should be dealt vigilantly. Wolters Kluwer - Medknow 2022-03 2022-03-24 /pmc/articles/PMC9129467/ http://dx.doi.org/10.4103/0019-5545.341979 Text en Copyright: © 2022 Indian Journal of Psychiatry https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Abstract- Poster Gracy*, Dr BK Sharma**, Dr Mini Kataria, Dr Dinesh Kukreti, Dr Prerna Submission for: Poster presentation at ANCIPS 2022: Allergic dermatitis with use of sublingual Buprenorphine: A rare case report |
title | Submission for: Poster presentation at ANCIPS 2022: Allergic dermatitis with use of sublingual Buprenorphine: A rare case report |
title_full | Submission for: Poster presentation at ANCIPS 2022: Allergic dermatitis with use of sublingual Buprenorphine: A rare case report |
title_fullStr | Submission for: Poster presentation at ANCIPS 2022: Allergic dermatitis with use of sublingual Buprenorphine: A rare case report |
title_full_unstemmed | Submission for: Poster presentation at ANCIPS 2022: Allergic dermatitis with use of sublingual Buprenorphine: A rare case report |
title_short | Submission for: Poster presentation at ANCIPS 2022: Allergic dermatitis with use of sublingual Buprenorphine: A rare case report |
title_sort | submission for: poster presentation at ancips 2022: allergic dermatitis with use of sublingual buprenorphine: a rare case report |
topic | Abstract- Poster |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9129467/ http://dx.doi.org/10.4103/0019-5545.341979 |
work_keys_str_mv | AT gracydrbk submissionforposterpresentationatancips2022allergicdermatitiswithuseofsublingualbuprenorphineararecasereport AT sharmadrmini submissionforposterpresentationatancips2022allergicdermatitiswithuseofsublingualbuprenorphineararecasereport AT katariadrdinesh submissionforposterpresentationatancips2022allergicdermatitiswithuseofsublingualbuprenorphineararecasereport AT kukretidrprerna submissionforposterpresentationatancips2022allergicdermatitiswithuseofsublingualbuprenorphineararecasereport |